DAVION HEALTHCARE PLC (DAVI) Davion Healthcare Plc is an Irish public limited company that develops and commercializes non-invasive home tests for the early detection of health anomalies, including cancers. Its products use thermography: a liquid crystal film placed on the skin shows temperature differences as color shifts, and AI analysis of smartphone images interprets the result. It has four completed tests, BreastCheck, FootFlow (diabetic circulation), Testic and ThermaDerm, all non-diagnostic Class I devices. BreastCheck and FootFlow have been FDA-registered, and registered in the EU and UK, since November 2023. Davion operates a licensing model and has a global manufacturing and distribution agreement for BreastCheck with NeuRX Health Inc., which provides $120 million in staged license fees and minimum annual royalties of $10 million over an initial ten-year term. The company was incorporated in Cyprus in 2022 and re-domiciled to Ireland in 2024, keeping a wholly owned Cyprus subsidiary. It plans to pair product commercialization with acquisitions of complementary healthcare businesses, and has launched a £30 million five-year senior secured bond through Davion Healthcare Finance Ltd. The listing is a direct listing of 25,000,000 existing ordinary shares, with no new capital raised.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Davion Healthcare Plc NASDAQ:DAVI Healthcare · Medical - Devices
Mkt Cap $25.75M
EV -
SI 4.6%
Net Cash/Sh -
CLOSED · Nov 17 +0.98%$1.03 CLOSED · Nov 17 Prev close $1.02 +0.98%Close $1.03 +0.97%AH close $1.04 VOL 186K $ Vol $192K RVOL 0.14x
Mkt Cap $25.75M
EV -
VOL 186K sh
$ Vol $192K
RVOL 0.14×
SI 4.6%
Net Cash/Sh -
Press Release
Davion Healthcare Plc Provides Shareholders with Guidance on Direct Registration and Confirmation of Share Ownership
Davion Healthcare issued shareholder guidance on how to directly register shares via the Direct Registration System with its transfer agent VStock Transfer (DRS #7924). The release responds to reported short-selling activity since the company's Nasdaq listing on October 22, 2026, though it explicitly does not allege improper trading by any market participant.
• 14h ago AI analysis › Press Release
Davion Healthcare Plc Agrees to Terms in Acquisition of Independence Care Homecare Network
Davion Healthcare's US subsidiary signed an agreement to acquire all businesses in the Independence Care homecare network — 14 businesses across ten US states — for total consideration of up to US$10 million. The targets generated combined revenues of approximately US$17 million in 2025, which Davion says will be accretive to the group. Consideration splits into $4.5M cash at signing, $3.5M cash plus $1M in DAVI shares at milestones, and up to $1M in earnouts tied to 2027-2028 performance.
• 1d ago AI analysis › Press Release
Davion Healthcare Plc Appoints Vienna Capital Partners to Support US$100 Million Acquisition Financing Strategy
Davion Healthcare has appointed Vienna Capital Partners as financial advisor to support a proposed US$100 million-plus acquisition financing strategy for 2027. The company intends to use senior secured, non-convertible institutional debt to fund multiple acquisitions of established, profitable US healthcare businesses, aiming to limit equity dilution.
• 11d ago AI analysis › Press Release ● Major
Davion Healthcare PLC Agrees $13.5 Million Acquisition of Profitable US Home Healthcare Business
Davion Healthcare has agreed to acquire Healthcare Stat Homecare, a profitable Philadelphia home healthcare provider, for $13.5 million — $8 million cash and $5.5 million in Davion shares at $13 per share. HSH reported roughly $11.6 million in gross receipts and about $1.9 million of unaudited business income for 2025, giving Davion an immediate revenue- and earnings-generating operating business. The deal is the first in a planned programme of acquisitions of profitable healthcare businesses over the coming year, and could eventually pair Davion's non-invasive monitoring technology with in-home care delivery.
• 19d ago AI analysis › Press Release
Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP
Davion Healthcare completed its first acquisition since last week's Nasdaq direct listing, buying the IP for WoundSkan (a smart wound-monitoring dressing) and the Spektra Lateral Flow Test for US$25 million. Consideration comprises US$2.5 million in cash plus 1,730,770 new Davion shares valued at a fixed US$13.00 per share; shares are issued after a 90-day deferral with sellers capped at 10% of five-day average daily volume for 90 days thereafter.
• 22d ago AI analysis › Press Release
DAVION HEALTHCARE PLC CONFIRMS EXPECTED NASDAQ TRADING DATE AND ANNOUNCES NEW EXECUTIVE LEADERSHIP AND OPERATING STRUCTURE
Davion Healthcare confirmed its ordinary shares are expected to begin trading on the Nasdaq Global Market on Thursday, October 22, 2026, under ticker DAVI. Glenn Williams will become CEO and Jeremy North COO upon commencement of trading, with current CEO Jack Kaye moving to Chairman and Sir Eric Peacock stepping down to Non-Executive Director. A new Operational Directorate will run commercialisation, operations and M&A execution. The company's flagship product is BreastCheck, an FDA-registered at-home breast health screening test, with a pipeline including FootFlow, Testic and ThermaDerm.
• 28d ago AI analysis ›